TRACON Pharmaceuticals Stock Price

-0.06 (-1.57%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
TRACON Pharmaceuticals Inc TCON NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.06 -1.57% 3.75 00:00:02
Open Price Low Price High Price Close Price Prev Close
3.75 3.71 3.815 3.75 3.81
Bid Price Ask Price Spread News
3.46 4.00 0.54 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,357 220,070 $ 3.75 $ 825,144 - 1.48 - 12.20
Last Trade Time Type Quantity Stock Price Currency
17:56:33 1 $ 3.80 USD


Draw Mode:

TRACON Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 58.13M 15.50M 9.30M $ - $ - -2.04 -2.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 63.00k 2.10%

more financials information »

TRACON Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TCON Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.703.953.513.80674,0650.051.35%
1 Month6.667.093.514.19481,447-2.91-43.69%
3 Months6.177.423.515.06255,930-2.42-39.22%
6 Months9.4011.763.517.56294,593-5.65-60.11%
1 Year1.7212.201.485.47771,5282.03118.02%
3 Years2.5012.200.27813.84461,0361.2550.0%
5 Years5.0912.200.27813.76320,719-1.34-26.33%

TRACON Pharmaceuticals Description

TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, TJ4309, Bispecific Antibodies.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.